|
|
Article: FDA Approves Dey, L.P.'s Perforomist(TM) (Formoterol Fumarate) Inhalation Solution for Maintenance Treatment of COPD.
- Article from:
- PR Newswire
- Article date:
- May 11, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-- First nebulized formoterol fumarate offers patients twice-daily dosing for rapid, long-lasting relief of emphysema and chronic bronchitis --
NAPA, Calif., May 11 /PRNewswire/ -- Dey, L.P. announced today that the Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Perforomist(TM) (formoterol fumarate) Inhalation Solution for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).
Formoterol is a rapid and long-lasting beta(2) agonist that has been previously approved in the U.S. as a dry powder formulation, and ...